Palo Alto, CALIFORNIA4 Active Studies

Temporal Lobe Epilepsy Clinical Trials in Palo Alto, CALIFORNIA

Find 4 actively recruiting temporal lobe epilepsy clinical trials in Palo Alto, CALIFORNIA. Connect with local research sites and explore new treatment options.

4
Active Trials
3
Sponsors
802
Enrolling

Recruiting Temporal Lobe Epilepsy Studies in Palo Alto

About Temporal Lobe Epilepsy Clinical Trials in Palo Alto

Temporal lobe epilepsy is the most common form of focal epilepsy, with seizures originating in the temporal lobe of the brain. It can cause unusual sensations, memory problems, and altered consciousness. Treatment includes antiseizure medications and surgery for drug-resistant cases.

There are currently 4 temporal lobe epilepsy clinical trials recruiting participants in Palo Alto, CALIFORNIA. These studies are seeking a combined 802 participants. Research is being sponsored by Biohaven Therapeutics Ltd., UniQure Biopharma B.V., Neurona Therapeutics. Clinical trial participation is free and participants receive study-related medical care at no cost.

Temporal Lobe Epilepsy Clinical Trials in Palo Alto — FAQ

Are there temporal lobe epilepsy clinical trials in Palo Alto?

Yes, there are 4 temporal lobe epilepsy clinical trials currently recruiting in Palo Alto, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Palo Alto?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Palo Alto research site will contact you about next steps.

Are clinical trials in Palo Alto free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Palo Alto studies also compensate for your time and travel.

What temporal lobe epilepsy treatments are being tested?

The 4 active trials in Palo Alto are testing new therapies including novel drugs, biologics, and treatment approaches for temporal lobe epilepsy.

Data updated March 2, 2026 from ClinicalTrials.gov